50
Participants
Start Date
July 23, 1998
Primary Completion Date
July 26, 2004
Study Completion Date
July 26, 2004
17-beta estradiol
5-15 mcg/kg daily for 2 years. Dose readjusted every 3 months. Administered orally
17-beta estradiol
0.2 mcg daily for 12 months, dose escalated to 0.5 mcg daily for 12 months. Administered orally
Novo Nordisk Investigational Site, Elche
Novo Nordisk Investigational Site, Cáceres
Novo Nordisk Investigational Site, Córdoba
Novo Nordisk Investigational Site, Santiago de Compostela
Novo Nordisk Investigational Site, Granada
Novo Nordisk Investigational Site, Jaén
Novo Nordisk Investigational Site, Madrid
Novo Nordisk Investigational Site, Madrid
Novo Nordisk Investigational Site, Madrid
Novo Nordisk Investigational Site, Madrid
Novo Nordisk Investigational Site, Madrid
Novo Nordisk Investigational Site, Madrid
Novo Nordisk Investigational Site, Málaga
Novo Nordisk Investigational Site, El Palmar
Novo Nordisk Investigational Site, Las Palmas
Novo Nordisk Investigational Site, Salamanca
Novo Nordisk Investigational Site, Santa Cruz de Tenerife
Novo Nordisk Investigational Site, San Cristóbal de La Laguna
Novo Nordisk Investigational Site, Santander
Novo Nordisk Investigational Site, Seville
Novo Nordisk Investigational Site, Valencia
Novo Nordisk Investigational Site, Valladolid
Novo Nordisk Investigational Site, Barakaldo
Novo Nordisk Investigational Site, Zaragoza
Novo Nordisk Investigational Site, Alicante
Novo Nordisk Investigational Site, Badajoz
Novo Nordisk Investigational Site, Esplugues Llobregat
Novo Nordisk Investigational Site, Tarrasa
Lead Sponsor
Novo Nordisk A/S
INDUSTRY